STAT+: Scholar Rock wins FDA approval for first drug to target SMA muscle loss

The U.S. Food and Drug Administration has granted approval to Scholar Rock for a new therapy designed to treat spinal muscular atrophy (SMA). This marks the first time a drug has been specifically authorized to target the loss of muscle associated with the rare neurological condition.

The approval offers a new treatment pathway for patients living with SMA. By focusing on muscle preservation, the therapy aims to improve physical outcomes, potentially increasing the ability of patients to move and walk independently.